Eterna Net Tangible Assets vs Short Long Term Debt Analysis
ERNA Stock | USD 1.90 0.07 3.83% |
Eterna Therapeutics financial indicator trend analysis is much more than just examining Eterna Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eterna Therapeutics is a good investment. Please check the relationship between Eterna Therapeutics Net Tangible Assets and its Short Long Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
Net Tangible Assets vs Short Long Term Debt
Net Tangible Assets vs Short Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eterna Therapeutics Net Tangible Assets account and Short Long Term Debt. At this time, the significance of the direction appears to have strong relationship.
The correlation between Eterna Therapeutics' Net Tangible Assets and Short Long Term Debt is 0.69. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Eterna Therapeutics, assuming nothing else is changed. The correlation between historical values of Eterna Therapeutics' Net Tangible Assets and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Eterna Therapeutics are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Net Tangible Assets i.e., Eterna Therapeutics' Net Tangible Assets and Short Long Term Debt go up and down completely randomly.
Correlation Coefficient | 0.69 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Most indicators from Eterna Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.As of June 1, 2024, Tax Provision is expected to decline to about 25 K. In addition to that, Selling General Administrative is expected to decline to about 13.6 M
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 74K | 30K | 614K | 644.7K | Depreciation And Amortization | 459K | 1.2M | 1.1M | 1.1M |
Eterna Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Eterna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eterna Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.3M | 12.9M | 32.4M | 22.3M | 49.1M | 51.6M | |
Other Current Liab | 1.6M | 975K | 247K | 4.0M | 3.1M | 2.0M | |
Total Current Liabilities | 6.1M | 3.1M | 3.7M | 7.7M | 6.6M | 5.9M | |
Total Stockholder Equity | 5.1M | 7.7M | 6.5M | 12.1M | 2.2M | 2.1M | |
Non Current Assets Total | 9.2M | 11.2M | 13.7M | 8.6M | 39.5M | 41.5M | |
Non Currrent Assets Other | 2.3M | 453K | 522K | 5.2M | 120K | 114K | |
Common Stock Shares Outstanding | 71.9K | 439.7K | 2.2M | 3.1M | 5.3M | 5.0M | |
Liabilities And Stockholders Equity | 15.3M | 12.9M | 32.4M | 22.3M | 49.1M | 51.6M | |
Non Current Liabilities Total | 4.1M | 2.1M | 22.3M | 2.5M | 40.3M | 42.3M | |
Other Current Assets | 526K | 102K | 1.1M | 2.2M | 1.6M | 2.3M | |
Other Stockholder Equity | 136.3M | (245K) | 165.9M | 177.4M | 189.2M | 131.8M | |
Total Liab | 10.2M | 5.2M | 25.9M | 10.2M | 46.9M | 49.2M | |
Total Current Assets | 6.1M | 1.7M | 18.8M | 13.7M | 9.6M | 9.8M | |
Short Long Term Debt Total | 6.1M | 2.9M | 2.7M | 4.1M | 41.8M | 43.9M | |
Property Plant And Equipment Net | 4.7M | 4.9M | 2.7M | 1.3M | 33.3M | 34.9M | |
Current Deferred Revenue | 460K | 76K | 1.2M | 190K | 218.5K | 207.6K | |
Net Debt | 2.8M | 1.3M | (14.3M) | (7.3M) | 34.3M | 36.0M | |
Retained Earnings | (131.5M) | (18.1M) | (159.7M) | (165.3M) | (187.0M) | (196.3M) | |
Accounts Payable | 835K | 1.3M | 1.8M | 1.6M | 1.1M | 764.4K | |
Cash | 3.3M | 1.6M | 17.0M | 11.4M | 7.6M | 6.1M | |
Cash And Short Term Investments | 3.3M | 1.6M | 17.0M | 11.4M | 7.6M | 6.1M | |
Net Receivables | 1.2M | 116K | 684K | 951K | 425K | 678.2K | |
Good Will | 1.0M | 667K | 696K | 2.0M | 2.4M | 1.4M | |
Accumulated Other Comprehensive Income | 200K | 268K | 245K | (1K) | (900.0) | (855.0) | |
Short Term Debt | 3.2M | 799K | 426K | 2.0M | 2.2M | 1.5M | |
Other Liab | 930.4K | 23K | 48K | 1.6M | 1.9M | 2.0M | |
Net Tangible Assets | 7.7M | 5.6M | 23.5M | 10.1M | 11.6M | 12.1M | |
Other Assets | 7.3M | 6.4M | 1K | 5.2M | 4.7M | 4.2M | |
Property Plant Equipment | 653.8K | 2.7M | 3.2M | 1.3M | 1.5M | 1.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Eterna Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.25) | Revenue Per Share 0.013 | Return On Assets (0.36) | Return On Equity (3.02) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.